Seikagaku Corporation
14
0
0
14
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 15/100
0.0%
0 terminated/withdrawn out of 14 trials
100.0%
+13.5% vs industry average
43%
6 trials in Phase 3/4
64%
9 of 14 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
A Study for Evaluation of the Efficacy and Safety of SI-614 Ophthalmic Solution in Patient With Dry Eye
Role: lead
SI-6603 (Condoliase) Study for Lumbar Disc Herniation (Discovery 6603 Study)
Role: lead
PK and Safety of SI-722 in IC/BPS
Role: lead
A Clinical Study Evaluating the Safety and Efficacy of SI-614 Ophthalmic Solution in Patients With Dry Eye.
Role: lead
A Clinical Study Evaluating the Safety and Efficacy of SI-614 Ophthalmic Solution in Patients With Dry Eye
Role: lead
A Study of SI-6603 in Patients With Lumbar Disc Herniation
Role: lead
A Study of SI-6603 in Patients With Lumbar Disc Herniation
Role: lead
Gel-One Treatment in Knee Osteoarthritis
Role: lead
Clinical Trial to Assess Safety of SI-6603 in Patients With Lumbar Disc Herniation
Role: lead
SI-6603 Versus Placebo in Patients With Lumbar Disc Herniation
Role: lead
SI-613 Study for Knee Osteoarthritis
Role: lead
Non-Inferiority Study Comparing 3 Weekly Injections of SUPARTZ® vs 3 Weekly Injections of Euflexxa® for Knee OA
Role: collaborator
Gel-200 Versus Placebo in Osteoarthritis of the Knee
Role: lead
Gel-200 Extension and Open-Label Study in Osteoarthritis of the Knee
Role: lead
All 14 trials loaded